To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: ACE Inhibitor Cleared For Post-MI Patients URL: http://www.pslgroup.com/dg/2E622.htm Doctor's Guide July 10, 1997
MT. OLIVE, N.J. -- July 10, 1997 -- The ACE (angiotensin converting enzyme) inhibitor Mavik(R) (trandolapril) has received U.S. Food and Drug Administration (FDA) clearance for marketing as maintenance therapy for patients with left ventricular dysfunction to prevent heart failure after myocardial infarction (MI), commonly known as heart attack. Mavik has been available in the United States since June 1996 for the treatment of hypertension when used alone or in combination with other antihypertensive medications. Mavik will be the lowest priced once-daily ACE inhibitor proven to increase survival in post-MI patients with left ventricular dysfunction. According to the American Medical Association, MIs are the most common cause of death in the United States -- but for every fatal heart attack there are at least two non-fatal ones. Post-MI drug treatments may include several prescription therapies, including Mavik, which reduces the workload of the heart muscle and helps improve the blood flow through coronary arteries by dilating both small arteries and veins. ACE inhibitors also counteract some of the substances produced by the kidneys that increase salt retention and can cause excessive constriction of small arteries. Mavik has been shown to increase survival in post-MI, reducing cardiovascular mortality by 25 percent, according to a statement released by Knoll Pharmaceutical Company, manufacturer and marketer of the product. A large clinical trial has shown that the product can achieve a significant reduction in mortality. Mavik offers convenient once-a-day dosing; dual route of elimination (via the kidneys and liver); and proven efficacy and safety in high-risk, post-MI patients, the company said. Mavik was studied in more than 1,700 post-MI patients at 27 sites during a two-year period. The results were published in the New England Journal of Medicine in late 1995. In clinical trials, Mavik was well tolerated, with the most common side effects being cough (35 percent), dizziness (23 percent) and hypotension (31 percent). --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.